Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981993 | 1.00 | KMT2A (0.53) | KMT2ASMN1; SMN2TDP1POLBHSD17B10 | |
| SCHEMBL9356442 | 0.89 | LMNA (0.41) | KMT2ASMN1; SMN2TDP1POLBHSD17B10 | |
| SCHEMBL11542934 | 0.85 | SMN1; SMN2 (0.56) | KMT2ASMN1; SMN2TDP1POLBL3MBTL1 | |
| SCHEMBL939646 | 0.84 | MMP2 (0.40) | KMT2ASMN1; SMN2TDP1POLBL3MBTL1 | |
| SCHEMBL10857529 | 0.84 | MAPT (0.52) | KMT2ASMN1; SMN2POLBMEN1ALDH1A1 | |
| SCHEMBL10857519 | 0.84 | MAPT (0.52) | KMT2ASMN1; SMN2POLBMEN1ALDH1A1 | |
| SCHEMBL939645 | 0.84 | MMP2 (0.40) | KMT2ASMN1; SMN2TDP1POLBL3MBTL1 | |
| SCHEMBL11541849 | 0.82 | ALDH1A1 (0.56) | KMT2ASMN1; SMN2TDP1POLBMEN1 | |
| SCHEMBL2982687 | 0.80 | CNR2 (0.46) | KMT2AMEN1LMNA | |
| SCHEMBL2982682 | 0.80 | CNR2 (0.46) | KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781613-B2 | Substituted N-aminomethylene sulfonamides, production and use thereof as medicaments | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | claimed |
| US-7781613-B2 | Substituted N-aminomethylene sulfonamides, production and use thereof as medicaments | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20080069851-A1 | SUBSTITUTED N-AMINOMETHYLENE SULFONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| CN-101107222-A | Substituted aminomethylene sulphonamides, production and use thereof as medicaments | SANOFI AVENTIS DEUTSCHLAND (FR) | 2008-01-16 | — | — | CN | disclosed |
| US-4940716-A | 2-amino-tetrahydro-isoquinolene derivatives and a process for the preparation thereof and pharmaceutical compositions containing same | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1990-07-10 | — | — | US | disclosed |
| US-4916149-A | Diuretic and saluretic 4-chloro-3-sulfamoylbenzoic acid hydrazides | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1990-04-10 | — | — | US | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
| US-4118397-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4111953-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4093735-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4010273-A | DIURETICS, SALURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080069851-A1 | SUBSTITUTED N-AMINOMETHYLENE SULFONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | LIPE, STS, ARSA | KMT2A 1903/4885SMN1; SMN2 3679/4885TDP1 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.